Get access to our best features
Get Started
Subscribe
Israeli-Palestinian Conflict
2024 US Election
US Politics
Baseball
US Economy
Donald Trump
US Crime
US Social Issues
Golf
Senate
Republican Party
Joe Biden
NFL
Get access to our best features
Get Started
Published 1 year ago

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer - Pfizer (NYSE:PFE), Merck (OTC:MKKGY)

Summary by Ground News
Merck KGaA regains exclusive rights to develop, manufacture, and commercialize Bavencio (avelumab) Pfizer will exit its global partnership over the PD-L1 MAb on 30 June. Pfizer shares are down 0.24% at $40.30 on the last check Monday.

0 Articles

All
Left
Center
Right
BenzingaBenzinga

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer - Pfizer (NYSE:PFE), Merck (OTC:MKKGY)

1 year ago·New York, United States
Read Full Article
HandelsblattHandelsblatt

Pharmaceutical industry: Pfizer returns rights to cancer immunotherapy Bavencio to Merck

Immunotherapy Bavencio was never able to fully meet these high expectations. Merck is now regaining full control over worldwide marketing.

1 year ago·Düsseldorf, Germany
Read Full Article
wiwo.dewiwo.de

Pharmaceutical industry: Pfizer returns rights to cancer immunotherapy Bavencio to Merck

Immunotherapy has never been able to fully meet these high expectations. Merck is now regaining full control over worldwide marketing.

1 year ago·Düsseldorf, Germany
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

EconomyEconomy
PfizerPfizer
MerckMerck
GermanyGermany
Germany EconomyGermany Economy
Trending Topics
Ground News logo
US
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble Newsletter
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal